Following disappointing clinical trial results with its KIT-targeting antibody briquilimab, Jasper Therapeutics is reducing its staff by approximately 50%. The clinical failures included loss of expected efficacy in a Phase 1b/2a hives trial and cessation of programs in asthma and severe combined immune deficiency. The company also announced leadership changes, shifting focus toward chronic spontaneous urticaria and streamlining development activities to conserve cash while extending its operational runway.